(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/208114 A1

(51) International Patent Classification:
A61K 31/395 (2006.01) *A61K 31/415* (2006.01)
A61K 38/16 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:
PCT/US2025/022176

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/572,081 29 March 2024 (29.03.2024) US
63/748,386 22 January 2025 (22.01.2025) US

(71) Applicant: **MAHA THERAPEUTICS, INC.** [US/US]; 4824 Saint Andrews Drive, Stockton, California 95219 (US).

(72) Inventor: **ALHAMADSHEH, Mamoun**; 4824 Saint Andrews Drive, Stockton, California 95219 (US).

(74) Agent: **SNYDER, Seth** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*


Published:
— *with international search report (Art. 21(3))*

(54) Title: CLEAVABLE CONJUGATES OF TRANSTHYRETIN LIGAND AND USES THEREOF

(57) Abstract: Provided herein are conjugates of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, L, L^B, E, and D^1 are as defined elsewhere herein. Also provided are methods of preparing compound of formula (I).

T—L—L^B—E—D^1 (I)

FIG. 17



WO 2025/208114 A1